The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
ettrading, certainly agree with you, there really does need to be more in terms of vetting to become a basic member on LSE. So many trolls and is so incessant at times.
If they can't provide more in terms of vetting, as I could see it being difficult, then if they could moderate the chats better that would be good. It's so obvious to see if someone is a de-ramper or ramper.
The value in diagnostics lies in knowing, it's in the name Omega DIAGNOSTICS... surely that's a big enough clue for you.
I would seriously suggest you go to their website - https://www.omegadiagnostics.com
Go through the RNS announcements and see whether or not we can make it to 75p or not... But I think we can go above and beyond that level very soon, inmo.
Whatever way you look at it, it doesn’t really matter inmo. What matters is that the whole thing will be expedited and RTC will see some juicy orders out of it, whenever that may be.
MIKODX, pretty sure we all knew what we were reading, it is people’s interpretation that was different. This was not going to fly on this type of news, it is just formalities it seems.
Looking forward to the next round of RNS and with Xmas coming, we all know what we have in store for us.
EUA is just a tool the FDA can use to get rapid tests over the line quickly, so this is will fly through the door and will get approved very fast.
Thanks to Royal Mail for clearing out post boxes 7 days a week!
https://www.sharebuyers.co.uk/shares/omega-diagnostics-qa-seize-significant-opportunity-ahead/
Thanks Trickymatters. So our potential early xmas present (tie up with Mologic), what are the margins for that do we know? Can see a 50% gross margin for RTC and 64% for non-Covid initiatives.
Thanks for your input Silverbackgirl...
Quickly someone, what is our average cost per Covid unit do we know? thanks.
No problem, thought you were someone else I follow on there. Very insightful person with very similar name to you!
Are you the same Bomber that’s on ADVFN?
I would say the stock market performed well under both Obama and Trump. Still though, hard to say for Biden.
Each administration comes with its separate ideas, but for the ones who do come in, they have a big job to do...!
For new investors looking in, this is not just great a great covid play, we are evidently diversified with our very own VISITECT CD4 test for HIV and now making great progress with Food Intolerance having now received Chinese approval.
A fantastic time to buy-in as we will be at the forefront of LFT devices and will be receiving many many orders, our CEO has done very well for has inmo and is very pragmatic in his approach. By April the SP will be many miles North of what it is now!
Looking through carados’ posting history explains a few things too
I don’t remember anything being mentioned in the presentation about further expansion of facilities.
I would have thought that ELISA gets parked whilst we meet the huge demand for antigen and antibody.
Clearly the ELISA test is competitive and we can instead focus on the LFTs, that’s what I would have liked to see, but that being said it could be harder than we know - it’s easy to criticise being sat in the comfort of our own homes, but I’ll finish off and say that our tests are the future.
You could hear it in CK’s voice, he could barely get his words out, he’s that excited!